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Pulmonary hypertension (PH) is a debilitating disease with a poor prognosis. Therapeutic options remain limited despite the
introduction of prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase 5 inhibitors within the last 15
years; these interventions address predominantly the endothelial and vascular dysfunctionS associated with the condition, but
simply delay progression of the disease rather than offer a cure. In an attempt to improve efficacy, emerging approaches have
focused on targeting the pro-proliferative phenotype that underpins the pulmonary vascular remodelling in the lung and
contributes to the impaired circulation and right heart failure. Many novel targets have been investigated and validated in
animal models of PH, including modulation of guanylate cyclases, phosphodiesterases, tyrosine kinases, Rho kinase, bone
morphogenetic proteins signalling, 5-HT, peroxisome proliferator activator receptors and ion channels. In addition, there
is hope that combinations of such treatments, harnessing and optimizing vasodilator and anti-proliferative properties, will
provide a further, possibly synergistic, increase in efficacy; therapies directed at the right heart may also offer an additional
benefit. This overview highlights current therapeutic options, promising new therapies, and provides the rationale for a
combination approach to treat the disease.
LINKED ARTICLES
This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit
http://dx.doi.org/10.1111/bph.2011.163.issue-1
Abbreviations
AC, adenylate cyclase; ACE., angiotensin converting enzyme; BH4, tetrahydrobiopterin; BMPR, bone morphogenetic
protein receptor; CCB, calcium channel blockers; CTEPH, chronic thromboembolic PH; eNOS, endothelial NO synthase;
EPC, endothelial progenitor cell; ERA, endothelin receptor antagonist; ERK1/2, extra-cellular signal regulated kinase;
ET-1, endothelin-1; FGF, fibroblast growth factor; IP, prostacyclin receptor; JAK/STAT, Janus kinase/signal transducer
and activator of transcription; Kv, voltage-sensitive potassium channel; MAPK, mitogen-activated protein kinase; NEP,
neutral endopeptidase; NP, natriuretic peptide; NPR, natriuretic peptide receptor; PAH, pulmonary arterial hypertension;
PDGF, platelet derived growth factor; pGC, particulate guanylate cyclase; PGI2, prostacyclin; PH, pulmonary
hypertension; PI3K, phosphoinositide-3-kinase; PKC, protein kinase C; PPAR, peroxisome proliferator activated receptor;
PPHN, persistent pulmonary hypertension of the newborn; PVR, pulmonary vascular resistance; ROCK, Rho-associated
kinase; SERT, 5-HT transporter; sGC, soluble guanylate cyclase; SNP, single nucleotide polymorphism; Src, Src kinase;
SSRI, selective 5-HT reuptake inhibitor; TGFb, transforming growth factor b; TRK, tyrosine kinase receptor; TRPC6,
transient receptor potential C6; TXA2, thromboxane A2; VEGF, vascular endothelial growth factor; VOCC, voltage
operated calcium channel; XNT, 1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulphonyl
oxy]-9H-xanthene-9-one)
BJP British Journal ofPharmacology
DOI:10.1111/j.1476-5381.2010.01164.x
www.brjpharmacol.org
British Journal of Pharmacology (2011) 163 125–140 125© 2011 The Authors
British Journal of Pharmacology © 2011 The British Pharmacological Society
Introduction
Pulmonary hypertension (PH) is a multi-factorial, progres-
sive disease with substantial mortality and morbidity.
Despite recent improvements in treatment, the mortality
associated with PH remains high, with survival at 2 years
from diagnosis approximately 85% (Thenappan et al., 2007;
National Pulmonary Hypertension Centres of the UK and
Ireland, 2008). Unfortunately, there remains no cure and
clinical worsening is merely delayed, not prevented, by
therapy (McLaughlin et al., 2009a,b). However, advances in
the understanding of PH aetiology and pathology have
yielded novel concepts, drug targets and treatment strategies
that may improve the management of patients with the
disease. This overview will provide a brief overview of the
current therapeutic options and highlight some of these
emerging therapeutic approaches which hold promise for
alleviating this debilitating disorder with an extremely poor
prognosis.
Pulmonary arterial hypertension
Since the World Health Organization (WHO) oversaw the
initial categorization of PH into ‘primary’ and ‘secondary’
forms in the early 1970 s, based on the presence or absence of
identifiable causes or risk factors, the clinical classification of
PH has undergone numerous modifications. The goal of the
current organization of PH is to group together different
manifestations of the disease, sharing similarities in patho-
physiological mechanisms, clinical presentation and thera-
peutic approaches (Figure 1; Simonneau et al., 2009).
Pulmonary arterial hypertension (PAH) is a subset of pul-
monary hypertensive syndromes, defined by a resting mean
1. Pulmonary Arterial Hypertension (PAH)
1.1. Idiopathic (IPAH)
1.2. Heritable/familial (FPAH) 
1.2.1. BMPR2
1.2.2. ALK1, Endoglin
1.2.3. Unknown
1.3. Drug and toxin-induced
1.4. Associated with (APAH) 
1.4.1.Conective tissue disorders
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis
1.4.6. Chronic haemolytic anaemia
1.5. Persistent  pulmonary hypertension of the newborn (PPHN)
1’. Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary haemangiomatosis (PCH)
2. Pulmonary hypertension with left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. Pulmonary hypertension due to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease (COPD)
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep disordered breathing
3.5. Alveolar hyperventilation disorders
3.6. Chronic exposure of high altitude
3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with indistinct, multi-factorial mechanisms
5.1. Haematological disorders (e.g. myeloproliferative disorders, splenectomy, haemoglobinopathies)
5.2. Systemic disorders (e.g. sarcoidosis, pulmonary Langerhans cell histocytosis , lymphangiomatosis)
5.3. Metabolic disorders (e.g. glycogen storage disease, Gaucher’s disease, thyroid disorders) 
5.4. Others (e.g. tumoural obstruction, fibrosing mediastinitis, chronic renal failure and dialysis)
Figure 1
Current classification of pulmonary hypertension.
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pulmonary artery pressure (PAP) > 25 mm Hg, pulmonary
vascular resistance (PVR) > 3 Wood units and pulmonary
wedge pressure <15 mmHg, in the absence of other causes of
PH (Archer et al., 1998). PAH is primarily a disease of the
small pulmonary arteries, characterized by vascular prolifera-
tion, remodelling and progressive increases in PVR, leading
ultimately to right ventricular failure and death (Voelkel
et al., 2006). PVR increases are attributed to endothelial dys-
function, resulting in vasoconstriction, remodelling of the
pulmonary vessel wall and thrombosis in situ (Budhiraja
et al., 2004). However, the haemodynamic aberrations
represent only one aspect of PAH, and enhanced prolifera-
tion, decreased apoptosis and a shift to glycolytic metabolism
in pulmonary artery smooth muscle cell fibroblasts and
endothelial cells is now recognized as central to the patho-
genesis of the disease. This pro-proliferative phenotype is
underpinned, at least in a subset of PAH patients, by aberra-
tions in transforming growth factor (TGF)b signalling. This
concept has been brought about by the identification of loss-
of-function mutations in the bone morphogenetic protein
receptor-2 (BMPR2) gene that promotes cell proliferation and
suppress apoptosis in 80% of familial PAH patients (Lane
et al., 2000). BMPR2 mutations are, however, uncommon in
non-familial PAH (10–20%) and even in familial PAH; disease
penetrance is low (only 25% of carriers develop the disease;
Newman et al., 2004). Single nucleotide polymorphisms
(SNPs) in ion channels (e.g. Kv1.5, TRPC6) and transporter
genes (SERT; molecular target nomenclature follows Alex-
ander et al., 2009) can also predispose to PAH and a multi-hit
hypothesis, a complex interaction between genes and envi-
ronment, has been proposed to explain the low disease pen-
etrance of genetic mutations in PAH [Figure 2; (Yuan and
Rubin, 2005; Newman et al., 2008)].
Current therapy
To date, clinical evaluation of novel therapies for PH has been
confined primarily to the PAH subset; there is only limited
randomized clinical trial evidence for other forms of PH, for
example, associated with lung disease and chronic throm-
boembolic PH (CTEPH), and research to establish effective-
ness of these therapies across PH classes is needed.
Nonetheless, advances made in the treatment of PAH are also
likely to be effective, to a greater or lesser extent, in patients
with aetiologically distinct forms of PH.
Many PH patients receive a background therapy of war-
farin, diuretics, digoxin and oxygen (McLaughlin et al.,
2009a,b). Anti-coagulant therapy with warfarin appears to
have beneficial effects on survival, at least based on findings
of observational studies (Johnson et al., 2006), while diuretics
limit oedema, and digoxin and oxygen provide symptomatic
relief. Frontline therapy aims at enhancing vasodilatation,
predominantly by inhibiting the bioactivity of endothelin-1
(ET-1), a potent endothelium-derived vasoconstrictor, or by
augmenting the vasodilator properties of nitric oxide (NO)
and prostacyclin (PGI2).
Ca2+ channel blockers
L-type Ca2+ channel blockers (CCB), such as. nifedipine, dil-
tiazem or amlodipine, can be effective in patients that
respond to a one-time vasodilator challenge with a >20% fall
in PAP and no decline in cardiac output (Rich and Brundage,
1987). Notably, only 10–15% of patients with iPAH meet
these criteria and only half of those will receive sustained
clinical and haemodynamic benefit. Patients who respond to
CCB therapy, however, have an excellent 5 year survival rate
(94%) as compared with those that do not respond [55%
survival; (Sitbon et al., 2005)].
Prostacyclin analogues
PGI2 and thromboxane A2 (TXA2) are arachidonic acid
metabolites with opposing vasoactivity. In PAH, the balance
is shifted towards vasoconstrictor, pro-proliferative TXA2
from vasodilator, anti-proliferative PGI2 (Christman et al.,
1992; Tuder et al., 1999). This relative impairment in PGI2-
dependent signalling in PAH leads to the development of
analogues that would mimic the cytoprotective activity of
this prostanoid and restore the balance between PGI2 and
TXA2. The beneficial activity of prostacyclin (analogues) in
PH is presumed to be via activation of the Gs-coupled IP
receptor, despite the fact that these compounds can activate
other prostanoid receptors (Narumiya et al., 1999); however,
recent evidence also supports a role for peroxisome prolifera-
tor activated receptors (PPARs; see below) in the underlying
mechanism.
Epoprostenol was the first treatment targeted directly at
PAH pathology, and has a proven survival advantage (Rubin
et al., 1990; Barst et al., 1996; Badesch et al., 2009). Its poor
stability, cost and the need for parenteral infusion, however,
have led to the development of more stable analogues with
more favourable means of administration and pharmacoki-
netic profiles; iloprost, trepostinil and beraprost are all used
in the clinical management of PAH patients.
Endothelin receptor antagonists (ERAs)
Plasma levels of ET-1, a potent vasoconstrictor and mitogenic
agent, are significantly elevated and correlate with disease
severity in PAH (Rubens et al., 2001). The action of ET-1 is
complex and mediated via two cell-surface, G-protein-
coupled receptors; ETA receptors on vascular smooth muscle
cells cause vasoconstriction and proliferation, while ETB
receptors on endothelial cells stimulate NO and prostacyclin
release, but on vascular smooth muscle cells induce vasocon-
striction and mitogenesis. Endothelin receptor antagonists
such as bosentan (dual ETA/ETB), ambrisentan (ETA > ETB) and
sitaxsentan (ET1A > > ETB) have been shown to improve pul-
monary haemodynamics, exercise capacity and reduce PAH
symptoms (Williamson et al., 2000; Channick et al., 2001;
Barst et al., 2004; Galie et al., 2005a); these drugs are of clini-
cal benefit, particularly in PAH associated with connective
tissue disease where they are often used as the initial treat-
ment option (Denton et al., 2008). However, a positive sur-
vival effect, and relative comparisons between ET-1 receptor
selective agents (selective ETA antagonists should possess a
theoretical advantage in not preventing the production of
NO via ETB receptor activation on endothelial cells) are still
lacking. Macitentan, a novel ETA/ETB receptor antagonist, is
currently in a phase III trial in PAH (SERAPHIN), after pro-
ducing a promising haemodynamic profile in a smaller Phase
II trial in hypertensive patients (Raja, 2010).
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PDE5 inhibitors
PDEs are homologous enzymes that facilitate the break-
down of the second messengers, cAMP and/or cGMP
(Bender and Beavo, 2006). There are 11 distinct PDE fami-
lies, with each typically consisting of several isoforms
and/or splice variants. Molecules blocking the activity of
this family of enzymes, collectively known as PDE inhibi-
tors, have been a major focus of drug development, particu-
larly for cardiovascular disease. Indeed, in the vasculature,
PDE inhibitors exert several favourable effects including
vasodilatation, inhibition of smooth muscle proliferation
and prevention of platelet aggregation (Bender and Beavo,
2006).
Blockade of PDE5, which metabolizes cGMP exclusively,
lowers systemic and pulmonary artery pressure under physi-
ological conditions in animals and humans (Jackson et al.,
1999; Madhani et al., 2006). Moreover, in animal models and
patients with PH, PDE5 inhibitors cause larger reductions in
pulmonary than systemic vascular resistance, thereby exhib-
iting relative selectivity for the pulmonary vasculature
(Klinger et al., 2006; Baliga et al., 2008). In accord, PDE5 is
found in abundance in the pulmonary vasculature and both
expression and activity are elevated in PAH (Murray et al.,
2002; Sebkhi et al., 2003). This favourable vasoactive profile
of PDE5 inhibitors has culminated in the development and
approval of sildenafil as a first-line therapy for PH; the drug
elicits an improvement in several indices of disease severity
Figure 2
Schematic representation of the current and emerging therapeutic targets for pulmonary hypertension outlined in this review. NP, natriuretic
peptide; NPR, natriuretic peptide receptor; PGI2, prostacyclin; ET-1, endothelin-1; BMPR, bone morphogenetic protein receptor; Kv, voltage-
sensitive potassium channel; KATP, ATP-sensitive potassium channel; TRPC6, transient receptor potential channel C6; VOCC, voltage operated
calcium channel; SERT, 5-HT transporter; NEP, neutral endopeptidase; NEPi, NEP inhibitor; BH4, tetrahydrobiopterin; eNOS, endothelial NO
synthase; TKR, tyrosine kinase receptor; ROCK, Rho-associated kinase; sGC, soluble guanylate cyclase; ERA, endothelin receptor antagonist; PDGF,
platelet derived growth factor; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor; AC, adenylate cyclase; IP, prostacyclin
receptor; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide-3-kinase; PKC, protein kinase C; Src, Src kinase; JAK/STAT, Janus
kinase/signal transducer and activator of transcription; PDE, phosphodiesterase; PDEi, PDE inhibitor.
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including pulmonary artery pressure, cardiac index, exercise
capacity and WHO functional class (Galie et al., 2005b).
Sildenafil also appears to produce an overall beneficial effect
on survival (Galie et al., 2009b). Tadalafil, an analogous PDE5
inhibitor with a longer half-life, has also been recently
licensed for the treatment of PAH (Galie et al., 2009a). A third
PDE5 inhibitor, vardenafil, is currently undergoing Phase III
evaluation for the same indication.
Inhaled NO
The inhalation of exogenous NO gas decreases PAP and
improves oxygenation in diverse forms of PAH, and is par-
ticularly effective in neonates suffering from persistent pul-
monary hypertension (PPHN; Roberts et al., 1992; Macrae
et al., 2004; Creagh-Brown et al., 2009). However, long-term
therapy with inhaled NO is complicated by the instability of
NO gas, concerns regarding the development of methaemo-
globinaemia (as NO binds avidly to, and oxidizes, the haem
moiety) and marked rebound pulmonary hypertension fol-
lowing cessation of therapy (Ichinose et al., 2004).
Novel therapeutic strategies
cGMP signalling
PDE5 inhibitors are an undoubted therapeutic advance, but
their effects on PAP are small (approximately 5 mm Hg reduc-
tion). A significant cohort of PH patients does not respond to
sildenafil treatment and in many individuals indices of
disease severity do not differ from placebo approximately 12
months after initiation of therapy. Moreover, in patients who
respond well to sildenafil, there is often a dose-dependent
systemic hypotension that limits the beneficial effects of the
drug. There is no evidence to suggest that the newer PDE5
inhibitors have a substantially greater effect than sildenafil,
or that sildenafil resistant patients respond to other PDE5
inhibitors. Thus, there remains considerable opportunity to
optimize interventions targeting cGMP-dependent signalling
to improve the treatment of PH.
In PH, pulmonary vascular cGMP levels are decreased,
either through impairment of NO bioavailability, guanylyl
cyclase inactivation [enzymes that generate cGMP in
response to NO and natriuretic peptides (Hobbs, 1997; Ahlu-
walia et al., 2004; Potter et al., 2006) or enhanced cGMP deg-
radation by PDEs (Crawley et al., 1992; Zhao et al., 1992;
Steudel et al., 1997; Archer et al., 1998). Accordingly, thera-
peutics targeted at augmenting cGMP levels have been shown
to have therapeutic value in PH, either in animal models or
patients with the disease.
NO donors. Attempts have been made to bypass the short
half-life and indiscriminate chemical reactivity of (inhaled)
NO, by developing more stable NO donors (e.g. NONOates),
which spontaneously release defined amounts of NO when
exposed to physiological pH. Daily nebulization with NON-
Oates (e.g. diethylenetriamineNONOate; DEA-NO) has
shown to be effective in animal models of PH (Vanderford
et al., 1994; Hampl et al., 1996). Similarly, older NO donors
such as glyceryl trinitrate administered by inhalation have
been shown to be effective in reducing PAP in small clinical
samples (Goyal et al., 2006). Thus, delivery of NO via more
sophisticated donor drugs may still prove to be efficacious in
PH patients. Nonetheless, concerns regarding the lack of pul-
monary selectivity, cGMP-independent cytotoxic effects and
rebound pulmonary hypertension remain relevant.
Endothelial NO synthase augmentation. A further mechanism
that may be exploited to treat PH is to improve endogenous
NO bioavailability by augmenting the activity of endothelial
NO synthase (eNOS). Expression and activity of eNOS, and
the availability of a key redox co-factor, tetrahydrobiopterin
(BH4), are largely reduced in PH (Giaid and Saleh, 1995; Shaul
et al., 1997; Le Cras et al., 1998; Khoo et al., 2005), and mice
with gene deletions in these systems are predisposed to the
disease (Fagan et al., 1999; Nandi et al., 2005; Leiper et al.,
2007). However, under some circumstances, eNOS may be
hyperactive in the pulmonary circulation in PH and, as a
result of inadequate supply of BH4, the enzyme uncouples to
form superoxide rather than NO (Zhao et al., 2009); this has
the doubly detrimental effect of scavenging NO and produc-
ing direct cytotoxicity.
Several approaches focusing on eNOS/BH4 have been
evaluated for efficacy in PH. First, supplementation with BH4
itself, or more promisingly an orally active, more stable form
(6R-BH4), is effective in augmenting endogenous BH4 levels,
restoring eNOS expression and reversing systemic hyperten-
sion (Landmesser et al., 2003); similar effects may be achiev-
able in PH. Second, the ‘eNOS coupling agent’, cicletanine,
has shown modest beneficial effects in animal models of PH
and humans with the disease (Jin et al., 1992; Saadjian et al.,
1998), presumably by coordinating eNOS activity with BH4
supply/binding and favouring the generation of NO over
superoxide (although increasing the endogenous formation
of PGI2 and natriuretic peptides may also underlie these posi-
tive effects). Cicletanine is currently under phase II evalua-
tion in patients with PAH. Thirdly, eNOS transcription
enhancers may prove advantageous in PH, as they have
shown in animal models to reverse the vascular remodelling
and cardiac hypertrophy associated with left-sided heart
failure (Westermann et al., 2009), ischaemia-reperfusion
injury [i.e. myocardial infarction (Sasaki et al., 2006; Frantz
et al., 2009)], and atherosclerosis (Wohlfart et al., 2008).
Finally, the Pulmonary Hypertension and Cell Therapy trial,
currently recruiting, is designed to test the safety and toler-
ability of autologous progenitor cell-based gene delivery of
human eNOS in patients with severe PAH. This study may
pave the way for more cell-based therapies for PAH, particu-
larly because endothelial progenitor cells are thought to play
a role in the pathogenesis of the disease (Toshner et al., 2009),
are a predictive biomarker and a novel therapeutic target (Yip
et al., 2008; Sun et al., 2009; Toshner et al., 2009; Fadini et al.,
2010).
Soluble GC activators. In order to harness the beneficial,
cytoprotective effects of cGMP while circumventing the
potentially detrimental cGMP-independent effects of NO,
the development of directly acting sGC ‘agonists’ has pro-
gressed in rapid fashion. Soluble GC appears a good target
in PH as the expression and activity of the enzyme is
up-regulated in order to compensate for decreased NO bio-
availability (Black et al., 2001; Schermuly et al., 2008; de
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Frutos et al., 2009) and genetic deletion of the enzyme results
in an exaggerated response to hypoxia-induced PH (Vermeer-
sch et al., 2007).
Two different classes of sGC ‘agonist’ have been devel-
oped. First, sGC ‘stimulators’ or ‘haem-dependent activators’
(e.g. BAY 41-2272, BAY 41-8543, BAY 63-2521, riociguat)
which stimulate the native Fe2+-sGC and synergize with NO
(Stasch et al., 2002a,b). Second, sGC ‘activators’ or ‘haem-
independent activators’ (e.g. BAY 58-2667, cinaciguat;
HMR-1766, ataciguat) which activate the proposed Fe3+ or
haem-free form of the enzyme and are additive with NO
(Belik, 2009; Schmidt et al., 2009; Stasch & Hobbs, 2009).
Both classes of drugs have been shown to have favourable
effects on experimental PH (Dumitrascu et al., 2006; Chester
et al., 2009; Weissmann et al., 2009). Riociguat, an orally
active sGC ‘stimulator’ is currently in Phase III trials for
determination of clinical effectiveness in idiopathic PAH and
CTEPH (Ghofrani et al., 2010). However, a limitation of this
sGC-centric strategy may be its lack of pulmonary selectivity,
as shown by the systemic hypotension observed in earlier
trials (Grimminger et al., 2009). This is perhaps not unex-
pected. Soluble GC ‘stimulators’ synergize with NO and will
therefore augment NO-dependent dilatation in all vascular
beds. Moreover, in PH the bioavailability of NO in the pul-
monary vasculature is known to be impaired, entailing that
this synergy will predominate in the systemic, rather than
pulmonary circulation. Nonetheless, these agents have exhib-
ited a favourable profile in Phase II trials and offer a novel
approach to treat PH; this therapeutic value may increase
with inhalation or combination therapy to target the sGC
‘stimulators’ to the pulmonary circulation (Evgenov et al.,
2007). In addition, Phase III evaluation of sGC ‘activators’
(e.g. cinaciguat) that preferentially trigger the oxidized form
of the enzyme, thought to be more prominent in diseased
vasculature, may provide a more pulmonary-centred thera-
peutic approach in PH. Indeed, cinaciguat has already exhib-
ited a favourable profile in patients with left-sided heart
failure (Lapp et al., 2009).
Natriuretic peptides. Atrial natriuretic peptide and brain
natriuretic peptide are synthesized by and released from
cardiac atrial and ventricular tissue, respectively, in response
to stretch and elicit falls in blood volume and blood pressure
(Ahluwalia et al., 2004; Potter et al., 2006). A third member of
the family, C-type natriuretic peptide, is released from the
vascular endothelium and regulates local blood flow in a
paracrine fashion (Ahluwalia and Hobbs, 2005). Each natri-
uretic peptide acts on specific cell-surface natriuretic peptide
receptors (NPR) in the vasculature which possess guanylate
cyclase functionality. The increase in tissue cGMP in response
to NPR activation brings about several cytoprotective effects
including natriuresis, vasodilatation, and anti-hypertrophic
and anti-proliferative activity [particularly in the heart
(Oliver et al., 1997)].
Genetic deletion of NPRs is associated with PH (Klinger
et al., 1999; Zhao et al., 1999; Kuhn, 2004), while administra-
tion of exogenous natriuretic peptides has been shown to
reduce hypoxia-induced PH (Klinger et al., 1999); such obser-
vations provide the rationale for therapeutic modulation of
natriuretic peptide signalling in PH. However, the short
plasma half-life and negligible oral bioavailability make natri-
uretic peptides poor candidates for drug therapy. An alterna-
tive strategy is to increase endogenous natriuretic peptide
levels by inhibiting the enzyme neutral endopeptidase (NEP),
a major degradative pathway for natriuretic peptides (and
other bioactive peptides) in the circulation (Okolicany et al.,
1992). This strategy has been proven to be effective in animal
models both as monotherapy (Klinger et al., 1993) and using
the NEP inhibitor racecadotril in combination with a PDE5
inhibitor (Baliga et al., 2008). Indeed, our data, both in vitro
and in vivo, suggest that PDE5 is pivotal in terminating the
cyclic GMP-dependent signalling in response to natriuretic
peptides in the pulmonary vasculature, whereas other PDE
isozymes regulate the vasorelaxant activity of natriuretic pep-
tides in the systemic circulation (Baliga et al., 2008). There-
fore, by inhibiting PDE5 in PH, in which circulating
natriuretic peptide concentrations are raised, it is possible to
target the pulmonary vasculature and reduce pulmonary
pressure. These observations explain the mechanism under-
pinning the pulmonary selectivity of PDE5 inhibitors and
suggest that in PH, the release of natriuretic peptides repre-
sents a cytoprotective mechanism that reduces disease pro-
gression. This thesis is in accord with studies reporting
increased expression and activity of PDE5 in the pulmonary
circulation of patients with PH (Wharton et al., 2005), that
the beneficial effects of PDE5 inhibitors in models of PH are
blunted in NPR-A knockout mice (Zhao et al., 2003) and that,
in patients with PH and animal models of the disease, acute
infusion of natriuretic peptides in the presence of sildenafil
synergistically reduces pulmonary artery pressure (Preston
et al., 2004; Klinger et al., 2006). Thus, the therapeutic poten-
tial of manipulating natriuretic peptide bioactivity to reverse
the haemodynamic abnormalities associated with PH holds
great promise. This is true not only for the haemodynamic
dysfunction, but also for attenuating the pulmonary vascular
re-modelling that also characterises the disease. Natriuretic
peptides inhibit pulmonary vascular smooth muscle prolif-
eration and TGFb-induced extracellular matrix expression in
vitro, and prevent structural changes in vivo in animal models
of PH (Jin et al., 1990; Klinger et al., 1998; 1999; Chen et al.,
2006; Li et al., 2007).
The strategy of targeting neutral endopeptidase for the
treatment of PH may also have the added benefit of slowing
the breakdown of other protective peptides that will contrib-
ute to efficacy, including adrenomedullin and vasoactive
intestinal peptide; both have been shown to be up-regulated
in PH and to reverse disease progression in animal models
(Shimokubo et al., 1995; Gunaydin et al., 2002; Matsui et al.,
2004; Qi et al., 2007; Said et al., 2007). However, NEP is also
important in the metabolism of ET-1, which may offset some
of its beneficial activity.
Other PDE inhibitors. PDE5 has received considerable atten-
tion in the context of PH due to the success of sildenafil and
other selective inhibitors. However, other isozymes (e.g. PDE1
and PDE3) are also up-regulated in PAH, and might be suit-
able targets for therapy.
PDE 1 and PDE 3 (and splice-variants thereof) have been
implicated in pulmonary vascular homeostasis and PH
(Bender and Beavo, 2006). These enzymes hydrolyse cGMP
and cAMP, although the PDE1A/1B splice variants have a
higher affinity for cGMP (Bender and Beavo, 2006). PDE1A
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and PDE1C expression and activity are up-regulated in
animal models of PH and in tissues from patients with the
disease (Evgenov et al., 2006; Murray et al., 2007; Schermuly
et al., 2007). Moreover, the selective PDE1 inhibitor,
8-methoxymethyl-isobutyl-1-methyl xanthine, reduces pro-
liferation of human vascular smooth muscle cells (Rybalkin
et al., 2002) and reverses the haemodynamic and morpho-
logical aberrations associated with monocrotaline and
hypoxia-induced PH (Schermuly et al., 2007).
PDE 3A/3B expression and activity are also enhanced in
PH (Murray et al., 2002), and the presence of this ‘cGMP-
inhibited’ PDE might underlie the synergistic cytoprotective
activity of NO and prostacyclin in PH, and explain the benefit
of co-administration of therapies promoting these pathways
concomitantly [i.e. sildenafil and iloprost (Wilkens
et al., 2001)]. Indeed, a dual PDE3/4 inhibitor reverses
monocrotaline-induced PH and synergizes with iloprost
(Schermuly et al., 2004; Dony et al., 2008). The PDE3 inhibi-
tor milrinone is currently being investigated for safety and
efficacy in treatment of PPHN, but despite this potential, the
increased mortality associated with the use of PDE3 inhibi-
tors in (left) heart failure (Amsallem et al., 2005) has limited
the therapeutic enthusiasm for this approach in PH.
Anti-proliferative pathways
PAH is characterised by a shift in the proliferative/apoptotic
balance and enhanced glycolytic metabolism (Mandegar
et al., 2004). Several growth factors, including platelet derived
growth factor (PDGF), fibroblast growth factor 2, epidermal
growth factor, vascular endothelial growth factor (VEGF) and,
more recently, the non-canonical Wnt pathway have been
implicated in the abnormal proliferation in PH (Oka et al.,
2007b; Hassoun, 2009; Izikki et al., 2009). Levels of PDGF and
its tyrosine kinase receptor PDGFR, are elevated in PAH
patient lung samples (Perros et al., 2008) and HIV-associated
PH samples (Humbert et al., 1998). VEGF levels are also
increased in plexiform lesions in PAH patients (Cool et al.,
1999). These growth factors act as potent mitogens and
chemoattractants, and through their transmembrane
tyrosine kinase receptor pathways activate major proliferative
signalling pathways such as the ras-mitogen activated protein
kinase (MAPK) cascade, resulting in proliferation, migration
and resistance to apoptosis (Hassoun, 2009). Consequently,
this has led to increased interest in translation of anti-
proliferative strategies, often originally developed for cancer
therapy, to PAH patients.
Tyrosine kinase inhibitors
Imatinib (Gleevac) was initially developed as an anti-cancer
therapy, predominantly chronic myelogenous leukemia, via
inhibition of the oncogenic tyrosine kinase Bcr-Alb, but was
later found to block the PDGFR and improve experimental
PH (Schermuly et al., 2005; Klein et al., 2008). Several case
studies of end-stage PH patients also suggest that treatment
with imatinib can improve clinical conditions (Ghofrani
et al., 2005; Patterson et al., 2006; Souza et al., 2006; Tapper
et al., 2009; Ten et al., 2009; Chhina et al., 2010). This has led
to a Phase III randomized, placebo-controlled clinical trial of
imatinib in PAH (IMPRES), from which results are eagerly
awaited. Nonetheless, there is some concern that long-term
of imatinib could be associated with left ventricular dysfunc-
tion and heart failure (Kerkela et al., 2006). Accordingly,
other tyrosine kinase inhibitors have been developed and
evaluated. Two such molecules are sunitinib and sorafenib,
multi-kinase inhibitors, blocking PDGF, VEGF and other pro-
proliferative signalling pathways. These molecules are cur-
rently being evaluated for safety and tolerability in Phase I,
and are undoubtedly efficacious in animal models of PH
(Klein et al., 2008; Gomberg-Maitland et al., 2010). However,
it remains to be seen if such molecules are also associated
with cardiotoxicity.
Several further molecules, often originally developed as
anti-cancer agents, have also been investigated in animal
models of PH, with positive outcomes, and are likely to lead
to clinical evaluation in patients with the disease, particularly
those molecules that are already licensed medicines. These
include cell cycle inhibitors [e.g. rapamycin (Paddenberg
et al., 2007)], anti-apoptotic drugs [e.g. survivin inhibitors
(McMurtry et al., 2005)] and elastase inhibitors (Merklinger
et al., 2005).
Rho kinase inhibitors
The Rho kinase pathway participates in vasoconstriction elic-
ited by numerous agents involved in PAH, including 5-HT,
ET-1 and TXA2 (Oka et al., 2008). Rho is a small monomeric
GTPase which activates Rho-associated kinase (ROCK) which
in turn phosphorylates and inhibits myosin light chain phos-
phatase, which leads to prolonged, refractory vasoconstric-
tion. Rho and ROCK also mediate smooth muscle cell
proliferation, in a 5-HT-BMPR dependent pathway, and have
been found to be elevated in smooth muscle cells from PAH
patients (Do e Z et al., 2009). Rho-kinase inhibitors have been
shown to reduce PH in many animal models, including the
monocrotaline rat, fawn hooded rats and chronic hypoxia/
SUGEN exposure (Oka et al., 2007a; Mouchaers et al., 2010).
In humans, Rho-kinase inhibition with fasudil shows modest,
immediate reductions in PVR, but this inhibitor of Rho-
kinase has to be administered by nebulization, that is,
directly into the lungs, to avoid systemic hypotension (Ish-
ikura et al., 2006; Fujita et al., 2010).
Bone morphogenetic protein
signalling pathway
The discovery of the association between mutations in
BMPR2 and PAH has led to increased interest in the BMP
signalling pathway as a therapeutic target (Lane et al., 2000).
BMPR2 is a constitutively active serine-threonine kinase and
a member of the TGFb superfamily. In response to ligand,
BMPR2 heterodimerises with one of four BMPR1 receptors
(BMPR1A, BMPR1B, Alk1, Alk2), and phosphorylates the
internal domain, triggering the cytosolic Smad protein sig-
nalling cascade (Yang et al., 2005). Activation of the MAPK
system [i.e. p38, extracellular signal regulated kinase 1/2 (ERK
1 /2) or Jun – N-terminal kinase] may also be an underlying
mechanism. While BMPR2 mutations are relatively rare in
non-familial PAH, dysfunctional BMPR signalling is often
seen in PAH. For example, the expression of BMPR2 protein is
markedly reduced in the lungs of patients with idiopathic
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PAH with no detectable mutation in BMPR2 (Atkinson et al.,
2002), and cells isolated from PAH patients show altered
response to BMP signalling (Morrell et al., 2001). Reduced
expression of BMPR2 is also found in the lungs of rats with
monocrotaline-induced pulmonary hypertension (Morty
et al., 2007)
Results of BMPR2-targetted therapy in animal models
have been mixed. Adenoviral gene delivery of BMPR2 failed
to reverse monocrotaline-induced PH (McMurtry et al., 2007),
but intravascular administration of BMPR2 with an endothe-
lial targeted vector in hypoxic rats produced better results
(Reynolds et al., 2007). In humans, BMPR2 mutations are
thought to result in direct inactivation of the receptor or
impaired trafficking of the receptor to the cell surface. Rescue
strategies using viral vectors or chemical chaperones to over-
come these aberrations are currently being investigated
(Sobolewski et al., 2008). Moreover, as pulmonary artery
smooth muscle cells from familial PAH patients demonstrate
increased sensitivity to TGFb signalling, molecules aimed at
blocking this pro-proliferative transduction system may be of
therapeutic utility (Morrell et al., 2001).
Peroxisome proliferator activated receptors
Recent observations suggest peroxisome proliferator acti-
vated receptors (PPARs) as another potential therapeutic
target in PH. PPARg is a downstream target of BMPR signalling
and mediates the inhibitory effect of BMP on PGDF-induced
smooth muscle cell proliferation (Hansmann and Zamanian,
2009) and PPARg null mice develop PAH (Guignabert et al.,
2009). Moreover, PPARg agonists have direct anti-
inflammatory, anti-proliferative and pro-apoptotic effects
(Hansmann et al., 2007; 2008). Rosiglitazone, a PPARg
agonist, is effective in reducing the PH produced in ApoE-/-
mice and reduces right ventricular hypertrophy and vascular
remodelling in hypoxia-induced PH (Crossno et al., 2007;
Nisbet et al., 2007). PPARs may also underpin some of the
beneficial effects of prostacyclin analogues in PH (Ali et al.,
2006; Falcetti et al., 2010; Harrington et al., 2010).
5-HT signalling blockers
The 5-HT (serotonin) is a potent pulmonary vasoconstrictor.
It was first implicated in the pathogenesis of PAH after out-
breaks of the disease in patients using the anorexigenic drugs,
aminorex and dexfenfluramine, appetite suppressants that
inhibit 5-HT uptake (Dempsie et al., 2008). 5-HT is synthe-
sized in pulmonary artery endothelial cells by the enzyme
tryptophan hydroxylase 1 (TPH1) and then then acts at one
of several 5-HT receptor subtypes (primarily 5-HT1B, 5-HT2A
and 5-HT2B) and through the 5-HT transporter (SERT), to
mediate constriction and proliferation of pulmonary artery
smooth muscle cells and fibroblasts (Welsh et al., 2004). This
results in a thickening of the medial layer and a narrowing of
the lumen of the pulmonary artery and contributes to the
pulmonary vascular remodelling associated with PAH. Down-
stream signalling molecules which play a role in 5-HT-
signalling include ROCK, p38 and ERK1/2. Plasma 5-HT levels
are elevated in PAH, as are SERT, 5-HT1B receptor and TPH1
expression in pulmonary artery smooth muscle and endot-
helial cells from PAH patients (MacLean and Dempsie, 2009).
In addition, endothelial cells from PAH patients generate
more 5-HT and proliferate more in response to 5-HT than
control cells (Eddahibi et al., 2001). Experimentally, the inhi-
bition of SERT prevents 5-HT-dependent proliferation in cells,
and reduces hypoxic PH in rodent models (Guignabert et al.,
2005; Song et al., 2005; Zhai et al., 2009; Zhu et al., 2009).
There is also evidence to suggest that 5-HT may interact with
BMPR2 to provide a ‘second hit’ risk factor for PAH (Long
et al., 2006; Willers et al., 2006). A single nucleotide polymor-
phism in the SERT gene has been identified in PAH patients
that appears to associate with higher SERT expression and
higher mean PAP, though this link has not been corroborated
in subsequent studies (Eddahibi et al., 2003; Machado et al.,
2006; Willers et al., 2006; Roberts et al., 2009). At present, a
number of drugs modifying 5-HT signalling are under clinical
evaluation for the treatment of PH, including terguride
(5-HT2A and 5-HT2B receptor antagonist), PRX-08066 (selective
5-HT2B receptor antagonist) and escilatorpram (selective 5-HT
re-uptake inhibitor, SSRI).
Renin-angiotensin-aldosterone axis
The renin-angiotensin-aldosterone system (RAAS) is up-
regulated in PAH (Cargill and Lipworth, 1995) and steps in
the RAAS system cascade appear to be viable therapeutic
targets in PH. Indeed, the ACE inhibitor captopril was evalu-
ated almost 20 years ago in PAH patients with some success
(Alpert et al., 1992). However, the development of more selec-
tive PAH therapies (i.e. specific to the pulmonary vasculature)
has diverted attention from the RAAS as a viable target.
Recently, the discovery that angiotensin-converting enzyme
2 (ACE2), a member of the vasoprotective arm of the RAAS, is
up-regulated in both experimental models of PH and human
PAH has refocused attention on this system (Ferreira et al.,
2009). ACE2 plays a regulatory role in the lung and activation
of endogenous ACE2 shifts the balance from the vasocon-
strictor, proliferative path (ACE/Angiotensin II/AT1 receptor)
to the vasoprotective anti-mitogenic path (ACE2/
Angiotensin1-7/Mas) of the RAAS. Over-expression of ACE2
(by lentiviral gene delivery) or an ACE2 activator, XNT,
reverses experimental PH (Ferreira et al., 2009; Shenoy et al.,
2010).
Statins
Statins offer a novel approach to the treatment of PAH. This
class of drugs have long been known to suppress vascular
inflammation and vascular smooth muscle cell proliferation
through a variety of mechanisms. In addition to lowering
cholesterol via inhibition of 3-hydroxyl-3-methyl glutaryl
CoA reductase, statins have been shown to have anti-
proliferative, anti-thrombotic, anti-inflammatory and anti-
oxidant effects, some of which may be secondary to
cholesterol lowering. Statins, in particular simvastatin, have
been reported to attenuate the development of PH in a
number of experimental animal models (Nishimura et al.,
2002; Girgis et al., 2003). Very recently, results from a double-
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blind, randomized, placebo-controlled study of the effects of
simvastatin added to optimized conventional care produced a
small and transient early reduction in right ventricular mass
and NT-proBNP levels in patients with PAH, but this was not
sustained over 12 months (Wilkins et al., 2010).
Ion channels
The haemodynamic dysfunction in PH patients also stems
from abnormalities in the activity of ion channels that
physiologically regulate local blood flow in the pulmonary
circulation. For example, down-regulation of voltage-gated
potassium channels, principally Kv1.5, appears to be a
common feature of animal models of PH and in humans with
the disease (Yuan et al., 1998; Pozeg et al., 2003). Targeting
this potassium channel in PH is attractive because the facili-
tation of K+ flux through this pore causes hyperpolarization,
vasodilatation, and is also thought to promote apoptosis. The
expression of Kv1.5 is inversely related to pulmonary vessel
size, suggesting that therapy would concentrate on the small
pulmonary arteries and thereby exert the greatest effect on
pulmonary vascular resistance (Pozeg et al., 2003). More
recently, interest has arisen in the transient receptor potential
(TRP) channel family. Experimental evidence suggests that
TRPC6 expression and activity is up-regulated in PH and this
leads to excessive Ca2+ entry into (pulmonary) vascular
smooth muscle cells and vasoconstriction (Yu et al., 2004), in
addition to PDGF-mediated proliferation (Schermuly et al.,
2005). Moreover, an SNP in the TRPC6 promoter appears to
associate with PH (Yu et al., 2009). Indeed, reversal of TRPC6
up-regulation may represent an added benefit of sildenafil
therapy in PH (Lu et al., 2010). Finally, KATP channel activators
such as iptakalim may have therapeutic utility in PH by
producing pulmonary vasodilatation and preventing
hypoxia- and ET-1-mediated pulmonary vascular smooth
muscle cell proliferation (Xie et al., 2004; Zhu et al., 2008).
Cardiac-targeted therapy:
b-adrenoceptor blockade
The major cause of death in PAH patients remains right
ventricular failure, and perhaps one of the most-overlooked
approaches in the treatment of the disease is cardiac-targeted
therapies. Such strategies may have little or no direct effects
on the pulmonary vasculature but prevent or reverse right
heart dysfunction; it is reasonable to predict that such a tactic
might make a major contribution to survival (Voelkel et al.,
2006).
The antagonism of b-adrenoceptors is a commonly used
strategy in patients with left-sided systolic heart failure, in
which mortality is reduced by approximately 30%, but is not
used clinically in right heart failure (i.e. PAH). The a1/b1/b2-
adrenoceptor blocker carvedilol and the selective b1-
adrenoceptor blockers, bisoprolol and metoprolol, reduce
mortality in patients with left-sided systolic heart failure with
a reversal of maladaptive cardiac remodelling, improved
cardiac function and prevention of arrhythmias (Bristow
et al., 1996; Fowler et al., 2007; MacGregor et al., 2009). b-
Adrenoceptor tachyphylaxis has also been demonstrated in
PAH and may contribute to maladaptive right ventricular
remodelling and the development of arrhythmias (Velez-Roa
et al., 2004). Carvedilol and metoprolol have been shown to
reverse right ventricular remodelling and improve right ven-
tricular function in experimental PH (Bogaard et al., 2010),
and the b-blocker arotinolol decreases both PAP and right
ventricular hypertrophy, without altering systemic blood
pressure, in a rat model of monocrotaline-induced PAH (Ish-
ikawa et al., 2009). Use of b-blockers in PAH has possible
detrimental effects on haemodynamics and exercise capacity.
While no specific clinical trial has been conducted to evaluate
the efficacy and safety of b-blockers in PAH, a small cohort of
porto-pulmonary hypertension patients were found to expe-
rience significant functional improvement following cessa-
tion of b-blocker therapy (Provencher et al., 2006), suggesting
a detrimental rather than beneficial outcome. Nonetheless,
further investigation of this class of anti-hypertensive medi-
cines may bring forth promising results in PAH patients.
Combination therapies
Since PH has a complex, multi-factorial aetiology, and the
fact that current treatments (and the vast majority of the
emerging therapies described previously) only target one
aspect of the disease, modern approaches have focused on
combining existing and newer therapies to bring about a
significant improvement in outcome. This is a logical
approach (based on the need for a combinatorial approach to
adequately control systemic hypertension) and many studies
suggest additive, if not synergistic, effects of combination
therapy in PH (Schermuly et al., 2001; Baliga et al., 2008).
Indeed, in clinical practice, combination therapy has become
the default position even though trial evidence to support
this strategy is limited. Small scale clinical evaluation of com-
binations of prostanoids, ERAs and PDE5 inhibitors have
been tried with some success (Ghofrani et al., 2002; Stiebelle-
hner et al., 2003; Stocker et al., 2003; Hoeper et al., 2004;
Humbert et al., 2004), with additional studies currently
recruiting [e.g. COMPASS-2 (sildenafil plus bosentan), STEP
(iloprost plus bosentan)]; however, validation of these com-
bination therapies will require further larger scale trials.
Moreover, these dual approaches have, to date, been
restricted to combinations of existing therapies which are
largely centred on the haemodynamic dysfunction. Newer
therapies, targeting cell proliferation rather than vasodilata-
tion, will necessarily entail novel combinations (as future
trials will be on a background of existing treatment).
Combination therapy, however, has important implica-
tions for the cost of treating PH patients, which at present is
approximately £45 000 per annum in the UK (National Insti-
tute for Health and Clinical Excellence). The partnership
between academia, the pharmaceutical industry and health-
care providers has been successful in developing treatments
for PH, but these drug costs pose a real challenge to health-
care systems. Exploring the potential of drug combination in
PH that include generic medicines, such as simvastatin
and racecadotril, has real potential for affordable drug
development.
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Conclusions
Advances in the treatment of PH over the past decade have
enabled physicians to substantially improve the prognosis,
yet the mortality rate remains high. Existing treatments are
based predominantly on vasodilatation, whereas many
emerging therapies are aimed at cell proliferation and
re-modelling (Figure 2). There is great optimism that this
alternative strategy will yield superior results, either alone or
in combination.
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